These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23892409)

  • 1. Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.
    Minicozzi P; Bella F; Toss A; Giacomin A; Fusco M; Zarcone M; Tumino R; Falcini F; Cesaraccio R; Candela G; La Rosa F; Federico M; Sant M
    J Cancer Res Clin Oncol; 2013 Sep; 139(9):1569-77. PubMed ID: 23892409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.
    Tokunaga E; Okada S; Yamashita N; Akiyoshi S; Kitao H; Morita M; Kakeji Y; Maehara Y
    Breast Cancer; 2012 Apr; 19(2):161-9. PubMed ID: 21063923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
    Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
    Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
    Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
    Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, mortality and receptor status of breast cancer in African Caribbean women: Data from the cancer registry of Guadeloupe.
    Deloumeaux J; Gaumond S; Bhakkan B; Manip M'Ebobisse N; Lafrance W; Lancelot P; Vacque D; Negesse Y; Diedhiou A; Kadhel P
    Cancer Epidemiol; 2017 Apr; 47():42-47. PubMed ID: 28119121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
    Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
    World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are breast cancer subtypes prognostic for nodal involvement and associated with clinicopathologic features at presentation in early-stage breast cancer?
    Jones T; Neboori H; Wu H; Yang Q; Haffty BG; Evans S; Higgins S; Moran MS
    Ann Surg Oncol; 2013 Sep; 20(9):2866-72. PubMed ID: 23661183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis.
    Caldarella A; Crocetti E; Bianchi S; Vezzosi V; Urso C; Biancalani M; Zappa M
    Pathol Oncol Res; 2011 Sep; 17(3):753-8. PubMed ID: 21479875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
    Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
    Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
    Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
    Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and survival outcome in cerebral metastatic breast cancer.
    Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
    Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
    Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
    Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.